SEHK:2161

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

HK$1.5b

Last Updated

2021/06/12 14:46 UTC

Data Sources

Company Financials

Executive Summary

JBM (Healthcare) Limited develops, manufactures, distributes, and markets healthcare and wellness products in Asia. More Details


Snowflake Analysis

Imperfect balance sheet with poor track record.

Share Price & News

How has JBM (Healthcare)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 2161 is more volatile than 90% of Hong Kong stocks over the past 3 months, typically moving +/- 17% a week.

Volatility Over Time: Insufficient data to determine 2161's volatility change over the past year.


Market Performance


7 Day Return

-5.7%

2161

2.4%

HK Pharmaceuticals

0.04%

HK Market


1 Year Return

n/a

2161

21.2%

HK Pharmaceuticals

25.7%

HK Market

Return vs Industry: Insufficient data to determine how 2161 performed against the Hong Kong Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how 2161 performed against the Hong Kong Market.


Shareholder returns

2161IndustryMarket
7 Day-5.7%2.4%0.04%
30 Day-8.8%14.1%4.2%
90 Day7.1%12.1%0.3%
1 Yearn/a23.0%21.2%30.5%25.7%
3 Yearn/a-11.8%-16.7%6.7%-4.6%
5 Yearn/a122.7%101.8%62.6%34.6%

Long-Term Price Volatility Vs. Market

How volatile is JBM (Healthcare)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is JBM (Healthcare) undervalued compared to its fair value and its price relative to the market?

29.04x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 2161 (HK$1.65) is trading above our estimate of fair value (HK$0.25)

Significantly Below Fair Value: 2161 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 2161 is poor value based on its PE Ratio (29x) compared to the Hong Kong Pharmaceuticals industry average (14.3x).

PE vs Market: 2161 is poor value based on its PE Ratio (29x) compared to the Hong Kong market (11.7x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 2161's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 2161 is overvalued based on its PB Ratio (1.8x) compared to the HK Pharmaceuticals industry average (1.3x).


Future Growth

How is JBM (Healthcare) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

16.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as JBM (Healthcare) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has JBM (Healthcare) performed over the past 5 years?

-21.8%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: 2161 has high quality earnings.

Growing Profit Margin: 2161's current net profit margins (10.8%) are lower than last year (17%).


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if 2161's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: 2161's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 2161 had negative earnings growth (-21.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (9.2%).


Return on Equity

High ROE: 2161's Return on Equity (6.2%) is considered low.


Financial Health

How is JBM (Healthcare)'s financial position?


Financial Position Analysis

Short Term Liabilities: 2161's short term assets (HK$270.1M) exceed its short term liabilities (HK$99.9M).

Long Term Liabilities: 2161's short term assets (HK$270.1M) do not cover its long term liabilities (HK$553.7M).


Debt to Equity History and Analysis

Debt Level: 2161's debt to equity ratio (69.1%) is considered high.

Reducing Debt: Insufficient data to determine if 2161's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: 2161's debt is not well covered by operating cash flow (7.8%).

Interest Coverage: 2161 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is JBM (Healthcare) current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 2161's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 2161's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 2161's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 2161's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 2161's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average board tenure


CEO

Patrick Wong (56 yo)

1.42yrs

Tenure

Mr. Yat Wai Wong is also known as Patrick is Chief Executive Director and Executive Director at JBM (Healthcare) Limited since January 7, 2020. He joined the Company and its subsidiaries since January 7, 2...


Board Members

Experienced Board: 2161's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: 2161 only recently listed within the past 12 months.


Top Shareholders

Company Information

JBM (Healthcare) Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: JBM (Healthcare) Limited
  • Ticker: 2161
  • Exchange: SEHK
  • Founded: 2020
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: HK$1.475b
  • Shares outstanding: 893.69m
  • Website: https://www.jbmhealthcare.com.hk

Location

  • JBM (Healthcare) Limited
  • Unit 2303-07, Tower 1
  • 23rd Floor, Millennium City 1
  • Kwun Tong
  • Kowloon
  • Hong Kong

Listings


Biography

JBM (Healthcare) Limited develops, manufactures, distributes, and markets healthcare and wellness products in Asia. It offers consumer healthcare and proprietary Chinese medicines, such as over-the-counter...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/12 14:46
End of Day Share Price2021/06/11 00:00
Earnings2020/03/31
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.